Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 6,519 |
|
|||||
| News | - | ||||||
| Day High | 1.36 | Low High |
|||||
| Day Low | 1.30 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Medicinova Inc | MNOV | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -0.76% | 1.31 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.33 | 1.30 | 1.36 | 1.31 | 1.32 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 98 | 6,519 | US$ 1.32 | US$ 8,574 | - | 1.26 - 2.66 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:32:00 | 10 | US$ 1.31 | USD |
Medicinova Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 64.74M | 49.05M | - | 1M | -8.57M | -0.17 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Medicinova News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNOV Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.40 | 1.41 | 1.30 | 1.35 | 11,268 | -0.09 | -6.43% |
| 1 Month | 1.45 | 1.6399 | 1.30 | 1.48 | 32,166 | -0.14 | -9.66% |
| 3 Months | 1.52 | 1.6399 | 1.26 | 1.40 | 51,491 | -0.21 | -13.82% |
| 6 Months | 1.94 | 2.16 | 1.26 | 1.74 | 84,386 | -0.63 | -32.47% |
| 1 Year | 2.20 | 2.66 | 1.26 | 1.84 | 52,010 | -0.89 | -40.45% |
| 3 Years | 4.51 | 5.09 | 1.26 | 3.56 | 166,603 | -3.20 | -70.95% |
| 5 Years | 10.99 | 13.37 | 1.26 | 6.63 | 285,023 | -9.68 | -88.08% |
Medicinova Description
| MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments. |
